Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The growth pattern of pilocytic astrocytoma (PAs) is unpredictable. Gene expression profiling has recently demonstrated an inverse relationship between myelin basic protein (MBP) expression and progression free survival (PFS) in PAs. We present here the pattern of expression of oligodendroglial differentiation markers (ODMs) in PAs by immunohistochemistry and their correlation with PI and PFS. Sixty-four cases of PA were reviewed and representative sections were stained for Ki-67 and ODMs, including MBP, platelet-derived growth factor receptor-alpha (PDGFR-alpha), Olig-1, and Olig-2. Sections were graded semi-quantitatively for intensity (I: 0-3+) and extent (E: 0-4+) of staining. PI was expressed as a percentage of Ki-67 positive cells. Immunoreactivity of MBP, PDGFR-alpha, Olig-1, and Olig-2 was observed in 84, 56, 97, and 75% of cases, respectively. There was a statistically significant inverse correlation between MBP expression and PI (r (2) = .696, p = .014). A positive correlation was observed between PDGFR-alpha and PI (r (2) = .727, p = .011). Further analysis showed a significant difference in PFS between low expressors [I + E score < or = 3] and high expressors (I + E score > or = 4) for PDGFR-alpha with p < .001. Notably, there was a significant difference in PFS between high expressors of MBP and high expressors of PDGFR-alpha with p < .001. These results suggest that expression of ODMs, especially MBP and PDGFR-alpha, may identify two clinical subsets of PA. In addition, we have shown the expression of 4 different ODMs in PAs, which may support the possibility that PAs arise from oligodendrocyte progenitor/precursor cells probably similar to the O2A progenitor cells in the mouse.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-007-9455-7DOI Listing

Publication Analysis

Top Keywords

high expressors
12
expression oligodendroglial
8
oligodendroglial differentiation
8
differentiation markers
8
clinical subsets
8
progression free
8
free survival
8
mbp expression
8
odms pas
8
pdgfr-alpha olig-1
8

Similar Publications

Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.

View Article and Find Full Text PDF

Aims: Schistosomiasis remains endemic in various parts of the world, and insights into pathogen immunobiology are mainly based on experimental models, while studies on human tissues are limited.

Methods: We explored the role of immune checkpoint pathway by evaluating the immunohistochemical expression of programmed death-ligand 1 (PD-L1) in a retrospective cohort of patients with bilharzial cystitis. Inflammation severity by conventional histology and staining intensity by immunohistochemistry were assigned three-tier scores (0/1+/2+), and a cut-off for staining percentage was set at 5%.

View Article and Find Full Text PDF

In patients with diffuse large B-cell lymphoma (DLBCL), concurrent deregulation of MYC and BCL2 confers inferior outcomes following R-CHOP. Dose-adjusted EPOCH-R (DA-EPOCH-R) produces favorable results in patients with dual MYC and BCL2 rearrangement (double-hit lymphoma, DHL), but there is limited prospective data in both DHL and DLBCL with dual protein overexpression of Myc and Bcl2 (double-expressor lymphoma, DEL). Lenalidomide (LEN) may enhance the response in MYC-driven lymphomas, prompting this investigator-initiated multicenter phase 1/2 study evaluating LEN with DA-EPOCH-R in adults with newly diagnosed DHL and DEL.

View Article and Find Full Text PDF

Double or Triple Hit Lymphomas (DHL/THL) represent a subset of aggressive B-cell lymphomas with markedly poorer outcomes and survival rates compared to Diffuse Large B-cell Lymphomas, NOS (DLBCL, NOS). Identifying the Hit status in High-grade large B-cell lymphoma (HGBL)/ Diffuse Large B-cell Lymphomas (used synonymously henceforth) can aid in identifying cases with aggressive clinical course that may benefit from more intensive chemotherapy. Utilizing immunohistochemistry (IHC) to detect Expressor Lymphomas (EL) provides a simpler and cost-effective means to screen DLBCL cases for further molecular studies aimed at identifying potential Hit status.

View Article and Find Full Text PDF

Background: Primary cardiac lymphoma (PCL) is a rare malignancy, representing a small fraction of primary cardiac tumors. Non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), a subtype of PCL, often presents with severe symptoms due to its cardiac involvement, and poses diagnostic and therapeutic challenges. This case highlights the use of an innovative surgical approach in managing a non-GCB primary cardiac DLBCL.

View Article and Find Full Text PDF